View ValuationCognetivity Neurosciences 将来の成長Future 基準チェック /06現在、 Cognetivity Neurosciencesの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Medical Equipment 収益成長17.3%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Oct 18Cognetivity Neurosciences Ltd. announced that it has received CAD 0.01 million in fundingOn October 17, 2023, Apogee 21 Holdings, Inc. closed the transaction. The transaction included participation from a single investorお知らせ • Jul 08Cognetivity Neurosciences Ltd. Announces Eisai's Leqembi Approval for the Treatment of Alzheimer's DiseaseCognetivity Neurosciences Ltd. announced that Eisai's Leqembi has achieved full FDA approval for the treatment of Alzheimer's disease, news that brings hope to tens of millions of sufferers and at-risk individuals worldwide. Leqembi received accelerated FDA approval in January 2023 due to its ability to clear amyloid plaques - harmful clumps of protein in the brain associated with Alzheimer's disease. Previously, the U.S. government's Medicare health plan for people aged 65 and over had restricted coverage only to patients in a clinical trial. Standard approval, the first of its kind for Alzheimer's disease, means that Leqembi will now be covered for all patients, although the Centers for Medicare and Medicaid Services (CMS) is linking reimbursement to patient participation in a health agency database, known as a registry. Since Alzheimer's is a disease of aging, most U.S. patients are insured by Medicare. CognICA is being used successfully to screen populations of individuals at risk of mild cognitive impairment, and reliably identifies those who show early signs of cognitive problems and require further assessment. Following clinical diagnosis, the technology platform is used to monitor changes in cognitive function among patients receiving monthly treatment, demonstrating the ability to deliver the CMS mandated reporting on patient progress. The speed, precision and ability to scale of CognICA give it a unique position in the market for the large-scale detection and monitoring of individuals with early stage Alzheimer's disease and other brain health issues. Cognetivity Neurosciences remains dedicated to utilizing its AI platform technology to transform the landscape of brain health globally, enhance the quality of care provided to patients and to reduce the burden and cost to providers and payers, delivering the company's vision of A Brighter Mind for a Fuller Life.お知らせ • Feb 16Cognetivity Neurosciences Ltd. Announces Release an Update Version of Its Tool, CognICATMCognetivity Neurosciences Ltd. announced that it has released an updated version of its tool, CognICATM. CognICA is a unique platform for the assessment and monitoring of brain health: powered by artificial intelligence (AI), FDA-registered and CE-marked, and commercially deployed in North America, East and Southeast Asia, the Middle East, and the UK's National Health Service (NHS). The company's technology uses AI and machine learning (ML) techniques to help detect the earliest signs of cognitive impairment by providing a fast, sensitive and objective measure of brain function. This enables CognICATM to facilitate the early identification of individuals with brain health issues, at a time when interventions are most effective, as well as supporting their long-term treatment management and monitoring. Crucially, as a fundamentally AI and ML-based tool, CognICA can be continually expanded and enhanced over time, trained on more data from an increasing number of global deployments to build increasingly refined, disease-specific models. In the case of Alzheimer's disease, for example, the company already holds a patent covering the use of an AI-based system to estimate levels of core biomarkers of neurodegeneration in the brain, such as amyloid (A) protein. The tool is tablet-based, self-administered and independent of language and education biases, thereby making it highly effective for comprehensive, scaled screening programs in all geographies. Among a range of improvements, the latest version of CognICA includes local data storage functionality, facilitating deployment in an expanded range of territories and thus enlarging the potential market for the technology. It also permits unlimited scaling, ensuring that users benefit from a rapid, efficient experience regardless of user load.お知らせ • Jan 25Cognetivity Neurosciences Ltd.'s CognICA Platform Successfully Monitors Cognitive Performance in Alzheimer's Patients Receiving Disease- Modifying TherapyCognetivity Neurosciences Ltd. announced that its CognICA tool has demonstrated effectiveness in tracking cognitive function during the treatment of Alzheimer's disease patients with the disease-modifying therapy Aduhelm (aducanumab), manufactured by Biogen. CognICA was used in clinical practice at Mediclinic Parkview Hospital in Dubai, UAE, to screen 108 patients coming into the neurology clinic for cognitive impairment. The tool was then used to monitor the cognition of the patients who received a diagnosis of Alzheimer's disease and were eligible for treatment with Aduhelm, a US Food and Drug Administration (FDA)-approved drug that directly targets amyloid beta pathology. The results showed that patients who received Aduhelm did not show cognitive decline, with two patients showing a significant improvement in cognitive performance. They demonstrate the use of CognICA as a sensitive screening and monitoring tool to support detection of cognitive impairment and measure changes in cognitive performance in response to disease-modifying therapies for Alzheimer's. As such, the tool is perfectly suited to support the dawning era of targeted therapies forneurodegenerative disease as evidenced by the FDA's approval, in the first week of 2023, of a second drug directly targeting amyloid beta pathology, LeqembiTM (lecanemab). Early detection and diagnosis will be critical to the rapid, large-scale rollout of this family of therapeutics since they havebeen approved for early-stage disease, in the form of mild cognitive impairment (MCI) or mild dementia due to Alzheimer's. Outstanding sensitivity to early-stage disease the ability to identify changes in the brain is CognICA's greatest strength, as demonstrated in thousands of patients and numerous peer-reviewed publications. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Cognetivity Neurosciences は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測OTCPK:CGNS.F - アナリストの将来予測と過去の財務データ ( )CAD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数10/31/20230-9-4-4N/A7/31/20230-8-4-4N/A4/30/20230-8-4-4N/A1/31/20230-7-6-6N/A10/31/2022N/A-10-5-5N/A7/31/2022N/A-14-6-6N/A4/30/2022N/A-14-6-6N/A1/31/2022N/A-13-3-3N/A10/31/2021N/A-9-4-4N/A7/31/2021N/A-3-3-3N/A4/30/2021N/A-3-2-2N/A1/31/2021N/A-2-2-2N/A10/31/2020N/A-1-1-1N/A7/31/2020N/A-2-1-1N/A4/30/2020N/A-2-2-2N/A1/31/2020N/A-3-2-2N/A10/31/2019N/A-3-2-2N/A7/31/2019N/A-3-3-3N/A4/30/2019N/A-3-3-3N/A1/31/2019N/A-4-4-3N/A10/31/2018N/A-4-3-3N/A7/31/2018N/A-4-3-3N/A4/30/2018N/A-3-2-2N/A1/31/2018N/A-1-1-1N/A10/31/2017N/A-1-1-1N/A1/31/2017N/A0N/A0N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: CGNS.Fの予測収益成長が 貯蓄率 ( 3.7% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: CGNS.Fの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: CGNS.Fの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: CGNS.Fの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: CGNS.Fの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: CGNS.Fの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YHealthcare 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/08/07 08:10終値2026/06/25 00:00収益2023/10/31年間収益2023/01/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Cognetivity Neurosciences Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Oct 18Cognetivity Neurosciences Ltd. announced that it has received CAD 0.01 million in fundingOn October 17, 2023, Apogee 21 Holdings, Inc. closed the transaction. The transaction included participation from a single investor
お知らせ • Jul 08Cognetivity Neurosciences Ltd. Announces Eisai's Leqembi Approval for the Treatment of Alzheimer's DiseaseCognetivity Neurosciences Ltd. announced that Eisai's Leqembi has achieved full FDA approval for the treatment of Alzheimer's disease, news that brings hope to tens of millions of sufferers and at-risk individuals worldwide. Leqembi received accelerated FDA approval in January 2023 due to its ability to clear amyloid plaques - harmful clumps of protein in the brain associated with Alzheimer's disease. Previously, the U.S. government's Medicare health plan for people aged 65 and over had restricted coverage only to patients in a clinical trial. Standard approval, the first of its kind for Alzheimer's disease, means that Leqembi will now be covered for all patients, although the Centers for Medicare and Medicaid Services (CMS) is linking reimbursement to patient participation in a health agency database, known as a registry. Since Alzheimer's is a disease of aging, most U.S. patients are insured by Medicare. CognICA is being used successfully to screen populations of individuals at risk of mild cognitive impairment, and reliably identifies those who show early signs of cognitive problems and require further assessment. Following clinical diagnosis, the technology platform is used to monitor changes in cognitive function among patients receiving monthly treatment, demonstrating the ability to deliver the CMS mandated reporting on patient progress. The speed, precision and ability to scale of CognICA give it a unique position in the market for the large-scale detection and monitoring of individuals with early stage Alzheimer's disease and other brain health issues. Cognetivity Neurosciences remains dedicated to utilizing its AI platform technology to transform the landscape of brain health globally, enhance the quality of care provided to patients and to reduce the burden and cost to providers and payers, delivering the company's vision of A Brighter Mind for a Fuller Life.
お知らせ • Feb 16Cognetivity Neurosciences Ltd. Announces Release an Update Version of Its Tool, CognICATMCognetivity Neurosciences Ltd. announced that it has released an updated version of its tool, CognICATM. CognICA is a unique platform for the assessment and monitoring of brain health: powered by artificial intelligence (AI), FDA-registered and CE-marked, and commercially deployed in North America, East and Southeast Asia, the Middle East, and the UK's National Health Service (NHS). The company's technology uses AI and machine learning (ML) techniques to help detect the earliest signs of cognitive impairment by providing a fast, sensitive and objective measure of brain function. This enables CognICATM to facilitate the early identification of individuals with brain health issues, at a time when interventions are most effective, as well as supporting their long-term treatment management and monitoring. Crucially, as a fundamentally AI and ML-based tool, CognICA can be continually expanded and enhanced over time, trained on more data from an increasing number of global deployments to build increasingly refined, disease-specific models. In the case of Alzheimer's disease, for example, the company already holds a patent covering the use of an AI-based system to estimate levels of core biomarkers of neurodegeneration in the brain, such as amyloid (A) protein. The tool is tablet-based, self-administered and independent of language and education biases, thereby making it highly effective for comprehensive, scaled screening programs in all geographies. Among a range of improvements, the latest version of CognICA includes local data storage functionality, facilitating deployment in an expanded range of territories and thus enlarging the potential market for the technology. It also permits unlimited scaling, ensuring that users benefit from a rapid, efficient experience regardless of user load.
お知らせ • Jan 25Cognetivity Neurosciences Ltd.'s CognICA Platform Successfully Monitors Cognitive Performance in Alzheimer's Patients Receiving Disease- Modifying TherapyCognetivity Neurosciences Ltd. announced that its CognICA tool has demonstrated effectiveness in tracking cognitive function during the treatment of Alzheimer's disease patients with the disease-modifying therapy Aduhelm (aducanumab), manufactured by Biogen. CognICA was used in clinical practice at Mediclinic Parkview Hospital in Dubai, UAE, to screen 108 patients coming into the neurology clinic for cognitive impairment. The tool was then used to monitor the cognition of the patients who received a diagnosis of Alzheimer's disease and were eligible for treatment with Aduhelm, a US Food and Drug Administration (FDA)-approved drug that directly targets amyloid beta pathology. The results showed that patients who received Aduhelm did not show cognitive decline, with two patients showing a significant improvement in cognitive performance. They demonstrate the use of CognICA as a sensitive screening and monitoring tool to support detection of cognitive impairment and measure changes in cognitive performance in response to disease-modifying therapies for Alzheimer's. As such, the tool is perfectly suited to support the dawning era of targeted therapies forneurodegenerative disease as evidenced by the FDA's approval, in the first week of 2023, of a second drug directly targeting amyloid beta pathology, LeqembiTM (lecanemab). Early detection and diagnosis will be critical to the rapid, large-scale rollout of this family of therapeutics since they havebeen approved for early-stage disease, in the form of mild cognitive impairment (MCI) or mild dementia due to Alzheimer's. Outstanding sensitivity to early-stage disease the ability to identify changes in the brain is CognICA's greatest strength, as demonstrated in thousands of patients and numerous peer-reviewed publications.